ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag economics disease medicine

A rendering of a human brain in blue on a dark background with blue and white lines surrounding the brain to represent the construction of new connections in the brain.
Defying Dogma: Decentralized Translation in Neurons
Danielle Gerhard, PhD | Sep 8, 2023 | 10+ min read
To understand how memories are formed and maintained, neuroscientists travel far beyond the cell body in search of answers.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Antibody Alternatives
Paul Ko Ferrigno and Jane McLeod | Feb 1, 2016 | 10+ min read
Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.
Top Ten Innovations 2010
Megan Scudellari | Dec 1, 2010 | 10+ min read
By The Scientist Staff Top Ten Innovations 2010 Innovative products that have the life science community buzzing. As the global economy continues to pull out of its recent precipitous nosedive, one mantra rings true from Beijing to Boston—innovation can save us. If developing interesting new technologies and products really is the lifeblood of economic health, then the life sciences industry is innovation’s beating heart. The Scientist rec
Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th
Opinion: Why Most TBI Studies Fail
Donald Stein | Feb 24, 2016 | 3 min read
Thoughts on how to redesign clinical trials for traumatic brain injury
Notebook
Paul Smaglik | Nov 21, 1999 | 6 min read
Contents Pivotal pump Leptin limbo Clue to obesity Biotech Web site Helping hand Mapping malaria UCSD - Salk Program in Molecular Medicine HEART FAILURE RESCUE: A cross section of a mouse genetically engineered to develop heart failure (left) shows enlarged heart chambers and thin walls that are typical of the condition. A cross section from the same strain of mouse, but with the phospholamban gene (PLB) also missing, appears normal. PIVOTAL PUMP A biochemical calcium pump and the gene that con

Run a Search

ADVERTISEMENT